Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 10/20 | 0.55 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.53 |
| ▸ | RXRA | P19793 | 1/20 | 0.49 |
| ▸ | RXRB | P28702 | 1/20 | 0.49 |
| ▸ | RXRG | P48443 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL423797 | 0.87 | MEN1 (0.62) | MAPTMEN1KMT2ADDR1ALDH1A1 | |
| SCHEMBL30628796 | 0.85 | CES2 (0.57) | TACR1P2RX1RXRARXRBRXRG | |
| SCHEMBL1040696 | 0.84 | PIK3CA (0.55) | CNR2MAPTMEN1KMT2ADDR1 | |
| SCHEMBL7194757 | 0.83 | TACR1 (0.51) | TACR1P2RX1CNR1CNR2MAPT | |
| SCHEMBL1515765 | 0.81 | MAPT (0.61) | CNR2MAPTMEN1KMT2AL3MBTL1 | |
| SCHEMBL423798 | 0.80 | DDR1 (0.59) | MAPTMEN1KMT2ADDR1CES2 | |
| SCHEMBL5641399 | 0.80 | ALDH1A1 (0.50) | TACR1P2RX1CNR1CNR2MAPT | |
| SCHEMBL1872900 | 0.80 | TACR1 (0.52) | TACR1P2RX1 | |
| SCHEMBL6970291 | 0.78 | CES2 (0.61) | MAPTMEN1KMT2ADDR1ALDH1A1 | |
| SCHEMBL504122 | 0.77 | RXRA (0.68) | TACR1RXRARXRBRXRGCES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029985-A1 | Process | AVECIA PHARMACEUTICALS LIMITED (GB) | 2010-02-04 | — | — | US | disclosed |
| EP-1851187-A1 | PROCESS FOR THE PREPARATION OF SECONDARY AMINES FROM KETONES | NPIL Pharmaceuticals (UK) Ltd (GB) | 2007-11-07 | — | — | EP | disclosed |
| WO-2006067395-A1 | PROCESS | AVECIA PHARMACEUTICALS LIMITED (GB) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029985-A1 | Process | ADH1A, ADH1C, AKR1C3 | TACR1 535/4885P2RX1 4104/4885RXRA 428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.